This study will evaluate whether participants with serious lung diseases such as idiopathic pulmonary fibrosis, sarcoidosis, and pulmonary hypertension who use the FORTISKAP™ smart medication cap - a bottle-top device that tracks prescription bottle openings and sends dose reminders to participants and their care team - take their medications more consistently and experience better health outcomes compared to similar participants receiving standard care without the device. Participation requires no changes to prescribed medications, testing or clinical visits beyond what is already part of routine care; participants use a modified medication bottle equipped with the FORTISKAP™ cap for nine months.
21 years of age or older at time of enrollment
Primary diagnosis of interstitial lung disease (including sarcoidosis) AND/OR pulmonary hypertension
Currently managing their oral medications independently (i.e., without requiring caregiver administration)
At least one oral medication with a primary indication for treatment of ILD or PH already in use, or planned for initiation with insurance approval secured, at the time of enrollment
None
Cosmos Rx, Inc
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Sentara Norfolk General Hospital
Collaborator